The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer (PDAC): Long-term outcomes and correlative insights.
 
Fergus Keane
No Relationships to Disclose
 
Richard Tuli
Consulting or Advisory Role - AstraZeneca
Research Funding - Abbvie (Inst); AstraZeneca
Patents, Royalties, Other Intellectual Property - patent pending: Methods of Treating Gastrointestinal Malignancies Application No.: 16/256,840 Filed: January 24, 2019 Inventor(s): Tuli, Richard (Inst)
 
Catherine A O'Connor
No Relationships to Disclose
 
Carly Schwartz
No Relationships to Disclose
 
Wungki Park
Honoraria - American Physician Institute; IntegrityCE
Consulting or Advisory Role - Astellas Pharma; Cerner Enviza; EXACT Therapeutics
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Break Through Cancer (Inst); Merck (Inst); Miracogen (Inst); NIH (Inst); NIH (Inst); Parker Institute for Cancer Immunotherapy (Inst); The Society of Memorial Sloan Kettering (Inst)
 
Anna M. Varghese
Consulting or Advisory Role - AstraZeneca (I); Lilly (I); PAIGE (I); Roche (I)
Research Funding - BioMed Valley Discoveries; Bristol-Myers Squibb; Illumina (I); Lilly; Silenseed; Verastem
Travel, Accommodations, Expenses - Roche (I)
 
Maria Perry
No Relationships to Disclose
 
Anupriya Singhal
No Relationships to Disclose
 
Santosha Vardhana
Honoraria - Agios
Consulting or Advisory Role - ADC Therapeutics; immunae
 
Andrew Eugene Hendifar
Consulting or Advisory Role - Amgen; Faraday Pharmaceuticals; Ipsen; Merus; Novartis; Pancreatic Cancer Action Network; Regeneron; Valar Labs; Varian Medical Systems
Research Funding - Ipsen; NGM Biopharmaceuticals (Inst)
Travel, Accommodations, Expenses - Halozyme
Other Relationship - Rayzebio
 
Zeynep Tarcan
No Relationships to Disclose
 
Olca Basturk
No Relationships to Disclose
 
Raymond S. McDermott
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Clovis Oncology; Ipsen; Janssen; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi
Speakers' Bureau - MSD Oncology
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Ipsen; Janssen-Cilag; Pfizer; Roche
 
Marsha Reyngold
No Relationships to Disclose
 
Christopher H. Crane
Stock and Other Ownership Interests - Oncternal Therapeutics
Honoraria - Elekta
Consulting or Advisory Role - TriSalus Life Sciences
Research Funding - Elekta (Inst)
 
Eileen M. O'Reilly
Consulting or Advisory Role - Abbvie (I); AstraZeneca; Autem Medical (I); Berry Genomics (I); BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Eisai (I); Exelixis (I); Genentech/Roche (I); Ipsen; J-Pharma (I); Merck; Merus; Novartis; QED Therapeutics (I); SERVIER (I); Tempus; Vector Health (I); Yiviva (I)
Research Funding - Agenus (Inst); Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Bristol Myers Squibb (Inst); Digestive Care (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Helsinn Healthcare (Inst); Parker Institute for Cancer Immunotherapy (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Yiviva (Inst)
(OPTIONAL) Uncompensated Relationships - Thetis Pharma
 
Joshua David Schoenfeld
No Relationships to Disclose